Catalent Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
Catalent Stock Forecast and Price Target
The average price target of $63.50 for Catalent's stock set by three distinguished analysts in recent weeks would represent a potential upside of approximately 13.8% from the last closing price in April, 2024 if reached by the end of the year. This potential increase is based on a high estimate of $63.50 and a low estimate of $63.50. Even if you are not interested in CTLT stock, it is still imperative to be aware of its competitors.
13.80% Upside
Catalent Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Catalent has seen a decline in its Price, from $68.26 to $0.00 – a 100.00% decrease. In the next year, analysts believe that Fair Value will reach $24.59 – an increase of 100.00%. For the next nine years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
10
|
$541.52 | Buy/Sell | $591.94 | 12.00% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$105.27 | Buy/Sell | $118.92 | 20.64% |
| IQV Stock Forecast | IQVIA Holdings | Outperform |
15
|
$227.17 | Buy/Sell | $267.27 | 21.05% |
| LONN Stock Forecast | Lonza Group | Buy |
16
|
CHF510.20 | Buy/Sell | CHF516.89 | 14.66% |
| A207940 Stock Forecast | Samsung Biologics | Buy |
7
|
₩790.00k | Buy/Sell | ₩0.00B | 32.91% |
Catalent Revenue Forecast for 2023 - 2025 - 2030
Catalent's Revenue has seen impressive growth In the last three years, rising from $3.09B to $4.26B – a growth of 37.78%. In the next year, analysts believe that Revenue will reach $4.36B – an increase of 2.21%. For the next nine years, the forecast is for Revenue to grow by 52.01%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ICLR Stock Forecast | ICON Public | Buy |
16
|
$291.82 | Buy/Sell | $306.07 | 22.51% |
| LH Stock Forecast | Laboratory Corp of America Hol... | Outperform |
11
|
$199.45 | Buy/Sell | $241.28 | 20.33% |
| 603259 Stock Forecast | WuXi AppTec | Buy |
18
|
¥43.43 | Buy/Sell | ¥121.48 | 54.89% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DGX Stock Forecast | Quest Diagnostics | Outperform |
10
|
$125.91 | Buy/Sell | $141.17 | 13.02% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.12 | Buy/Sell | $11.73 | 7.91% |
| 500124 Stock Forecast | Dr. Reddy's Laboratories | Hold |
18
|
Rp5.96k | Buy/Sell | Rp5.67k | 1.53% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ERF Stock Forecast | Eurofins Scientific | Hold |
18
|
60.08€ | Buy/Sell | 0.00€ | -1.80% |
| DIVISLAB Stock Forecast | Divi's Laboratories | Hold |
18
|
Rp3.71k | Buy/Sell | Rp3.30k | -9.27% |
| CRL Stock Forecast | Charles River Laboratories Int... | Outperform |
16
|
$227.55 | Buy/Sell | $229.97 | 21.62% |
Catalent EBITDA Forecast for 2023 - 2025 - 2030
Catalent's EBITDA has decreased In the last three years, from $660.00M to $629.00M – a 4.70% drop. Analysts predict that Catalent's EBITDA will increase in the upcoming year, reaching $719.15M. This would represent an increase of 14.33%. Over the next eight years, experts predict that Catalent's EBITDA will grow at a rate of 189.98%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 2269 Stock Forecast | WuXi Biologics (Cayman) | Outperform |
8
|
HK$13.24 | Buy/Sell | HK$69.40 | 60.27% |
| DCC Stock Forecast | DCC | Buy |
18
|
£54.45 | Buy/Sell | £67.24 | 28.93% |
| 300759 Stock Forecast | Pharmaron Beijing | Outperform |
16
|
¥18.87 | Buy/Sell | ¥37.14 | 42.45% |
Catalent EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Catalent's EBIT has seen a drop from $406.00M to $207.00M – a 49.01% decrease. In the next year, analysts believe that EBIT will reach $393.01M – an increase of 89.86%. For the next seven years, the forecast is forEBIT to grow by 477.33%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 002821 Stock Forecast | Asymchem Laboratories (Tianjin... | Outperform |
16
|
¥78.41 | Buy/Sell | ¥170.73 | 37.23% |
| SFZN Stock Forecast | Siegfried Holding | Outperform |
18
|
CHF877.00 | Buy/Sell | CHF891.22 | 17.50% |
| PRGO Stock Forecast | Perrigo Co PLC | Outperform |
16
|
$29.94 | Buy/Sell | $44.75 | 33.60% |
Catalent EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Catalent has seen a decline in its EPS, from $2.11 to $0.00 – a 100.00% decrease. In the next year, analysts believe that EPS will reach $0.76 – an increase of 100.00%. For the next nine years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| EVT Stock Forecast | Evotec | Outperform |
14
|
13.45€ | Buy/Sell | 37.33€ | 89.59% |
| 603456 Stock Forecast | Zhejiang Jiuzhou Pharmaceutica... | Buy |
18
|
¥15.12 | Buy/Sell | ¥37.79 | 58.73% |
| 300363 Stock Forecast | Porton Pharma Solutions | Outperform |
18
|
¥16.57 | Buy/Sell | ¥37.00 | 72.00% |
.jpg)